Drugs / FOR-6219
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04686669 | Dec 2020 → Jan 2021 | — | Forendo Pharma Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03709420 | Aug 2018 → Nov 2020 | endometriosis | Forendo Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOR-6219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04686669 ↗ |
| Action | Inhibit | “a hydroxysteroid (17B) dehydrogenase (HSD17B1) inhibitor” NCT03709420 ↗ |
| Route | Oral | “Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.” NCT03709420 ↗ |
| Target | HSD17B1 | “a hydroxysteroid (17B) dehydrogenase (HSD17B1) inhibitor” NCT03709420 ↗ |